Deciphering Ibogaines Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses
Christopher HwuiD, Václav HaveliD, Xavier O. WestergaardiD, Adriana M. Mendieta, Inis C. SerranoiD, Jennifer Hwu, Donna M. WaltheriD, David LankriiD, Tim Luca SelingeriD, Keer HeiD, R. Liu, Tyler P Shern, Steven Sun, Boxuan Ma, Bruno GonzáleziD, Luisina Rodriguez, Hannah J. GoodmaniD, Hunter Wu, Mark S. Sonders, Michael H. BaumanniD, Ignacio CarreraiD, David L. SulzeriD, Dalibor SamešiD
Abstract
Ibogaine is the main psychoactive alkaloid produced by the iboga tree (Tabernanthe iboga) that has a unique therapeutic potential across multiple indications, including opioid dependence, substance use disorders, depression, anxiety, posttraumatic stress disorder (PTSD), and traumatic brain injury (TBI). We systematically examined the effects of ibogaine, its main metabolite noribogaine, and a series of iboga analogs at monoamine neurotransmitter transporters, some which have been linked to the oneiric and therapeutic effects of these substances. We report that ibogaine and noribogaine inhibit the transport function of the vesicular monoamine transporter 2 (VMAT2) with sub-micromolar potency in cell-based fluorimetry assays and at individual synaptic vesicle clusters in mouse brain as demonstrated via two-photon microscopy. The iboga compounds also inhibit the plasma membrane monoamine transporters (MATs), prominently including the serotonin transporter (SERT), and a novel iboga target, the organic cation transporter 2 (OCT2). SERT transport inhibition was demonstrated in serotonin axons and soma in the brain and in rat brain synaptosomes, where ibogaine and its analogs did not act as substrate-type serotonin releasers. Noribogaine showed dual inhibition of VMAT2 and SERT with comparable potency, providing an explanatory model for the known neurochemical effects of ibogaine in rodents. Together, the updated profile of the monoamine transporter modulation offers insight into the complexity of the iboga pharmacology, which we termed "matrix pharmacology". The matrix pharmacology concept is outlined and used to explain why ibogaine and noribogaine do not induce catalepsy, as demonstrated in our study, in contrast to other VMAT2 inhibitors. TOC Graphic O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=110 SRC="FIGDIR/small/641351v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@a1cacaorg.highwire.dtl.DTLVardef@8be27org.highwire.dtl.DTLVardef@1fc320forg.highwire.dtl.DTLVardef@3a8837_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 7
- FWCI
- 8.22
- Field percentile
- top 2%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Addiction States
V. Havel, A. C. Kruegel, … D. Sames·bioRxiv·Jul 22, 2021
- Structure-based Discovery of Conformationally Selective Inhibitors of the Serotonin Transporter
I. Singh, A. Seth, … G. Rudnick·bioRxiv·Jun 13, 2022
- Noribogaine effects on wakefulness and sleep
Juan Pedro Castro‐Nin, Diego Serantes, … Joaqúın González·bioRxiv·Jul 26, 2023
- Extracellular flux analysis and proteomic profiling indicate ibogaine promotes synaptic plasticity and neural repair by a metabolic preconditioning mechanism
Madison J Oulton, Gracious D. S. Kasheke, … George S. Robertson·bioRxiv·Oct 2, 2026
- Development of Bioisosteric Iboga-alkaloids as Antinociceptive and Anxiolytic Agents with Neuroprotective Effects
Abhishek Gupta, Tuhin Bhattacharya, … Surajit Sinha·bioRxiv·Feb 24, 2025
- Gamma band alterations and REM-like traits underpin the acute effect of the atypical psychedelic ibogaine
Joaqúın González, Matías Cavelli, … Pablo Torterolo·ACS Pharmacology & Translational SciencePeer-reviewed·Jan 11, 2021